

Wednesday, September 11, 2013

11:00 AM - 12:30 PM

Session 1: Biologic and molecular characterization of Acute Myeloid Leukemia

Chairmen: Clara Bloomfield, Sante Tura

- Secondary AML
- Clinical impact of NPM1 mutations in AML
- Prognostic impacts and clonal heterogeneity of recurrently identified mutations in AML
- The role of the microenvironment in ALs

Valeria Santini
Konstanze Döhner

Hitoshi Kiyoi
Jacques Ghysdael

12:30 PM - 1:00 PM

Kenneth McCredie Memorial Lecture

Introduction: Roland Mertelsman

Clinical significance of prognostic molecular markers in adult AML

Clara Bloomfield

1:00 PM - 2:00 PM **Lunch**

2:00 PM - 4:00 PM

Session 2: Treating Acute Myeloid Leukemia today

Chairmen: Alan K. Burnett, Charles Schiffer

- Is APL a cured disease-what are the future challenges?
- Treatment options for AML in the elderly
- How should we manage AML in adolescents and young adults (AYA)?
- Who should be transplanted in first remission of AML?
- Genotype-adapted treatment trials in AML-Concepts of the AMLSG

Francesco Lo Coco
Sergio Amadori

Richard Larson

Alan K. Burnett

Hartmut Döhner

4:00 PM - 5:00 PM **Open Coffee**



4:00 PM - 6:00 PM

Session 3: Treating Acute Myeloid Leukemia tomorrow

Chairmen: Cestmir Altaner, Tomoki Naoe

- Therapeutic targeting of miR-associated mechanisms in AML
- Targeting mutated epigenetic modifiers in AML
- Where can we really use MRD in AML (excluding APL)?
- The future for immune therapy in AML. Stop being so negative
- GVHD and GVL: perspectives to modulate them in allotransplant for AML

Guido Marcucci
Ross Levine

David Grimwade

Michael Caligiuri

Arnon Nagler

6:00 PM - 6:30 PM

Yohei Ito Memorial Lecture

Introduction: Tomoki Naoe

Is the new molecular subgrouping of AML clinically helpful and can new, specifically targeted, AML drugs be developed?

Charles Schiffer

6:30 PM - 8:00 PM

Opening Ceremony and Welcome Cocktail

Thursday, September 12, 2013

8:15 AM - 10:15 AM

Session 4: Multiple Myeloma

Chairmen: Kenneth C. Anderson, Mario Boccadoro

- Staging and prognosis of multiple myeloma
- First line therapy for young patients
- First line therapy for elderly patients
- New drugs in multiple myeloma
- Curing myeloma – How to define and accomplish

Mario Boccadoro
Elena Zamagni
Antonio P. Palumbo
Kenneth C. Anderson

Bart Barlogie

10:00 AM - 11:00 AM **Open Coffee**

10:15 AM - 12:30 PM

Session 5: Acute Lymphoid Leukemia

Chairmen: Carmino De Souza, Robin Foà

- ALL therapy in adults
- ALL therapy in children
- T ALL: new therapeutic perspectives?
- Transplant in ALL: which one and when
- Ph-positive ALL: the German approach
- Ph-positive ALL: the Italian approach

Dieter Hoelzer
Andrea Biondi
Jan Cools
Hervé Dombret
Oliver Ottmann
Robin Foà

12:30 PM - 1:00 PM

John Moloney Memorial Lecture

Introduction: Federico Caligaris-Cappio

B-raf and HCL

Brunangelo Falini

1:00 PM - 2:00 PM **Lunch**

2:00 PM - 3:30 PM

Session 6: Focus on iron

Chairmen: Clara Camaschella, Eliezer Rachmilewitz

- Molecular biology of iron overload
- Methods to quantify iron overload
- Intracellular damage of iron overload in MDS
- Chelation therapy in chronic anemias
- Chelation therapy in MDS

Clara Camaschella
Antonio Piga
Eliezer Rachmilewitz
Maria D. Cappellini
Daniela Cilloni



3:30 PM - 4:00 PM

Peter Hans Hofschneider Memorial Lecture

Introduction: John Goldman

Animal Models to study human leukemogenesis

Rick Van Etten

4:00 PM - 5:00 PM **Open Coffee**

4:00 PM - 5:30 PM

Session 7: Focus on Stem Cell Transplant

Chairmen: Jane Apperley, Angelo Michele Carella

- Haploidentical transplant
- Cord blood transplant
- Transplant in CML
- Allo SCT for congenital anemias:
the example of Diamond Blackfan disease

Nicholas Kröger
Francesco Frassoni
Jane Apperley

Franca Fagioli

5:30 PM - 6:00 PM

Howard Temin Memorial lecture

Introduction: Tariq Mughal

Deconstructing the molecular genetics of human
leukemia and its therapeutic implications

Pier Paolo Pandolfi

6:00 PM - 7:30 PM

Celgene Sponsored Symposium with Cocktail Dinner

Therapeutic Strategies for Haematological Malignancies - an Update

Chairman: Wolf-Karsten Hofmann

- Welcome and introduction
- Status quo on the treatment of
lower-risk del(5q) MDS patients
- Emerging maintenance strategies for
AML patients undergoing intensive therapy
- Opportunities in the changing treatment
landscape of MM
- Novel treatment strategies in PTCL
- Discussion and close

Wolf-Karsten Hofmann

Valeria Santini

Alan Burnett

Antonio Palumbo

Paolo Corradini

Wolf-Karsten Hofmann

Friday, September 13, 2013

8:30 AM - 10:30 AM

Session 8: MPNs

Chairmen: Francisco Cervantes, Tariq Mughal

- New mutations and pathogenesis of myeloproliferative neoplasms
- Preclinical models of novel targets for treatment
- Management of polycythemia vera
- Prognostic scores in primary myelofibrosis
- Therapeutic approaches in myelofibrosis

William Vainchenker

Alessandro M. Vannucchi

Tiziano Barbui

Francisco Cervantes

Giovanni Barosi

10:00 AM - 11:00 AM Open Coffee

10:30 AM - 12:30 PM

Session 9: Chronic Myeloid Leukemia

Chairmen: Francois Guilhot, Anna Turkina

- ELN recommendations in 2013
- New prognostic markers in CML
- First line therapy in CML: which is the best?
- Can treatment discontinuation become the ultimate goal of CML therapy?
- New targets in CML therapy
- Open problems in CML research

Michele Baccarani

Martin Müller

Andreas Hochhaus

François Guilhot

Danilo Perrotti

John Goldman

12:30 PM - 1:00 PM

Sol Spiegelman Memorial Lecture

Introduction: Arsène Burny

CML in 2013: how can we best predict and improve outcome?

Rüdiger Hehlmann

1:00 PM - 2:00 PM Lunch and Poster walking

Chairmen: Felicetto Ferrara, Giorgina Specchia

1:00 PM - 1:45 PM IACRLRD General Assembly

2:00 PM - 4:00 PM

Session 10: Myelodysplastic Syndromes

Chairmen: Michael Lübbert, Norbert Vey

- Genetic Alterations in MDS: which are the driver mutations?

H. Phillip Koeffler



- Towards a molecular classification and prognostication of MDS Mario Cazzola
- Therapeutic interventions to target the molecular defects in lower-risk MDS Eva Hellström-Lindberg
- Recent advances in epigenetic therapy of MDS and secondary AML Michael Lübbert
- Activities of the GFM-Study-Group: from anti-angiogenetic therapy to allografting of MDS Norbert Vey
- Activities of the German MDS Research Consortium Wolf-Karsten Hofmann

4:00 PM - 5:00 PM **Open Coffee**

4:00 PM - 5:30 PM

Session 11: Chronic Lymphocytic Leukemia

Chairmen: Federico Caligaris-Cappio, Marina Liberati

- Molecular pathogenesis of CLL and its evolution Davide Rossi
- Prognostic markers in CLL Emili Montserrat
- Monoclonal B-cell lymphocytosis Paolo Ghia
- Molecular genetics of high-risk chronic lymphocytic leukemia Gianluca Gaidano
- Novel therapies for CLL Amy J. Johnson

5:30 PM - 6:00 PM

Frank Rauscher Memorial Lecture

Introduction: Tariq Mughal

Hematological neoplasms after exposure to ionizing radiations

Robert P. Gale

6:00 PM - 7:30 PM

Novartis Sponsored Symposium with Cocktail Dinner

Optimal management of Myeloproliferative disorders

Chairmen: Francis Giles, Gianantonio Rosti

- Path to cure: protocols aiming to therapy discontinuation François-Xavier Mahon
- Endpoints and surrogate markers in clinical trials Joëlle Guilhot
- How to eradicate the minimal residual disease in CML Francis Giles
- New perspective in the management of MPNs Francesco Passamonti

Saturday, September 14, 2013

8:30 AM - 10:00 AM

Session 12: Nanotechnologies for innovative clinical research

Chairmen: Giovanni Martinelli, Fabrizio Pane

- Methods to identify novel candidate cancer genes:
what is new? Alessandro Morotti
- The “essential” molecular lab for present clinical practice Fabrizio Pane
- Whole genome sequencing: a true perspective
in clinical practice? Giovanni Martinelli
- Ultra-deep sequencing: the future of
mutation analysis? Simona Soverini

10:00 AM - 11:00 AM **Open Coffee**

10:00 AM - 12:30 PM

Session 13: Viruses and hematological malignancies

Chairmen: Luigi Chieco Bianchi, Genoveffa Franchini

- Models for HIV eradication strategies Genoveffa Franchini
- B cell lymphoma in HIV infection - does HIV
have anything to do with it? Alfredo Garzino Demo
- Hematological neoplasms and viral Infections Toshiki Watanabe
- Adult T-Cell leukemia Arinobu Tojo
- Regulation of oligoclonality in HTLV-1
infection Charles R.M. Bangham
- Historical overview on the roots of
comparative research in leukemia Günter Pasternak

12:30 PM - 1:00 PM

Charlotte Friend Memorial Lecture

Introduction: Toshiki Watanabe

PNH: a clonal non-neoplastic hematopoietic disease Lucio Luzzatto

1:00 PM - 2:00 PM **Lunch**



2:00 PM - 2:30 PM

Special Lecture

Introduction: Giuseppe Saglio

Molecular pathogenesis of Diffuse Large B cell lymphomas

Riccardo Dalla Favera

2:30 PM - 4:30 PM

Session 14: Lymphoid malignancies

Chairmen: Riccardo Dalla Favera, Stefano Sacchi

- Follicular Lymphomas
- Diffuse Large B-Cell Lymphomas therapy
- The predictive value of PET
- Auto and allo transplantation in PTCL: what can be considered a standard?

Corrado Tarella
Carmino De Souza
Andrea Gallamini

Paolo Corradini

4:30 PM - 4:45 PM Closing remarks

Giuseppe Saglio